U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients

Endocrine Practice

Volumn 18, Issue 1, 2012, Pages 34-38

  Ziesmer, Anne E ^a   Kelly, Kevin C ^a   Guerra, Patricia A ^a   George, Karen G ^a   Dunn, Fredrick L ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; HEMOGLOBIN A1C; INSULIN DERIVATIVE; PIG INSULIN; TRIACYLGLYCEROL; U 500; UNCLASSIFIED DRUG;

ADULT; AGED; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; REVIEW; TREATMENT DURATION; VETERAN;

ADULT; AGED; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRIGLYCERIDES; VETERANS;

EID: 84857550327     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11043.OR     Document Type: Review

References (14)

1. Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;29:2504-2505.
2. Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010;33:281-283.
3. Dailey AM, Williams S, Taneja D, Tannock LR. Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract. 2010;88:259-264.
4. Garg R, Lawrence IG, Akinsola MO, Davies MJ, McNally PG. Improved glycaemic control in severely insulin resistant, insulin-treated diabetic paients with U500 Actrapid over two year follow-up [Abstract]. Diabetologia. 2004;47(Suppl 1):149.
5. Nayyar V, Jarvis J, Lawrence I, Kong M-F, et al. Long- term follow up of patients on U-500 insulin: a case series. Pract Diab Int. 2010;27:194-197.
6. Neal JM. Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr Pract. 2005;11:305-307.
7. Wafa WS, Khan MI. Use of U-500 insulin in type 2 diabetes. Diabetes Care. 2006;29:2175-2176.
8. Humulin R regular U-500 (concentrated) insulin [package insert]. Indianapolis, IN: Eli Lilly & Co; 2000.
9. Jackson JA, de la Pena A, Morrow LA, et al. Human regular insulin U-500 shows prolonged time-to-peak effect and longer duration of action vs human regular insulin U-100 in healthy obese subjects. Abstract presented at: ADA Scientific Sessions; June 28, 2010; Orlando, FL.
10. Khan M, Lee YY. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy subjects [Abstract]. Diabetes. 2007;56(Suppl):1294.
11. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240-1244.
12. Dunn FL. Management of dyslipidemia in people with type 2 diabetes mellitus. Rev Endocr Metab Disord. 2010;11:41-51.
13. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462.
14. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15:71-79.